Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2012

View Archived Issues

New potential antibodies for anticancer use developed in U.S.

Potent novel ALK inhibitors presented

New dual allosteric Akt inhibitors show promise in cancer models

Antiglaucoma agent ATS-8535 characterized in vitro and in vivo

Novel HealOr product accelerates corneal healing

CNK1 PH domain investigated as a target for KRas-mutant cancer

Mitsubishi Tanabe Pharma reviews highlights of fiscal 2011

Research in U.K. links SNP to systemic sclerosis risk

Japanese phase II study of ONO-2745 completed

FDA committee votes on approval of Quad regimen

Phytopharm reports on preclinical Myogane study

Depomed receives milestone payment from Ironwood Pharmaceuticals

Kancera compounds show promise in cancer treatment

Theratechnologies' TH-1173 enters preclinical safety phase

Arno Therapeutics product obtains orphan drug status for NF2

New data presented on brentuximab vedotin in cutaneous T-cell lymphoma

Proximagen designs novel chemokine CXCR4 receptor antagonists

Novel OSM-directed antibodies created at Janssen Biotech

AstraZeneca presents new transient receptor potential TRPA1 channel antagonists

Research at Amicus yields new pharmacological chaperones

Novel candidate drugs for Alzheimer's disease patented

Islet Sciences licenses technology from Yale University

Galapagos kicks off new study of novel JAK1 inhibitor

Health Canada grants Apricus Biosciences meeting for nail fungus therapy

Mologen study meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...